# Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

> **NCT01918241** · PHASE2 · UNKNOWN · sponsor: **Hangzhou Jiuyuan Gene Engineering Co. Ltd.,** · enrollment: 200 (estimated)

## Conditions studied

- Neutropenia

## Interventions

- **DRUG:** pegfilgrastim,30mcg/kg
- **DRUG:** pegfilgrastim, 60mcg/kg
- **DRUG:** pegfilgrastim, 100mcg/kg
- **DRUG:** filgrastim, 5mcg/kg

## Key facts

- **NCT ID:** NCT01918241
- **Lead sponsor:** Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2016-01
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2015-11-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01918241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01918241, "Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01918241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*